Benitec Biopharma Limited (ASX:BLT)
has welcomed publications of independent research supporting Tribetarna for additional cancer indications.
The biotechnology company believes the findings from universities in Sydney and Germany provide potential for its Tribetarna program to expand beyond lung cancer.
CEO and Managing Director Dr Peter French says it is pleasing to see Beneitec’s target gene for non-small cell lung cancer being implicated in an ever-widening range of solid cancers.
The news comes in the same week Benitec advised a third patient in the clinical trial of its TT-034 treatment of Hepatitis C has been dosed and the results are set for review in six weeks.
Benitec Biopharma reported a net loss of $7.03 million in the 2014 financial year.